HB4834 proposes amendments to the Illinois Controlled Substances Act’s Prescription Monitoring Program provisions (720 ILCS 570/316) to exclude testosterone and certain specified drugs (including mifepristone, misoprostol, GnRH analogues, and estrogen) from PMP applicability as described in the research text. It would also add a new Section 316.2 requiring the Department to purge existing PMP records concerning testosterone by 2027-01-01 and ensure no further testosterone records are created/maintained, with associated rules updates by 2027-01-01. If enacted, this would change PMP reporting scope, downstream analytics, and record retention/purge obligations for covered entities and the administering Department; compliance teams should monitor bill status and assess impacts to PMP submission and data governance processes.
SB3213 (104th GA) proposes amendments to the Illinois Controlled Substances Act (and related Pharmacy Practice Act provisions) addressing electronic prescribing and prescription transfers. As described in the research text, the bill would (if enacted) clarify that Schedule II prescriptions may be transferred only once and not further transferred, aligning with federal rules (21 CFR 1306). It would also expand/clarify exceptions to mandatory electronic prescribing for Schedules II–V where electronic prescribing is impractical and delay would adversely impact the patient, including circumstances such as filling outside typical retail pharmacy hours and drug shortages/inventory limitations. The bill passed the Senate on 2026-04-16 and was sent to the House on 2026-04-17; compliance teams should track enactment because it would affect pharmacy transfer procedures and prescriber/pharmacy eRx exception documentation practices.
An amendment (ham002) to Illinois HB1811 was filed on 2026-04-02 proposing changes to 720 ILCS 570/201 (Illinois Controlled Substances Act, Section 201). The amendment would adjust the Department’s authority and procedures for adding, deleting, or rescheduling controlled substances (including timelines tied to federal scheduling actions), establish/modify an objection and hearing process, and include provisions referencing security controls/exceptions affecting DEA-registered manufacturers/distributors. Compliance teams should monitor because it could change how and when Illinois scheduling changes are implemented following federal actions, potentially impacting substance control status and facility security expectations.
Illinois SB3507 (104th GA) saw committee activity on 2026-03-04 (postponed in Senate Licensed Activities). The proposal would amend Illinois Controlled Substances Act PMP-related requirements (referenced in research as 720 ILCS 570/314.5) to broaden documentation expectations around attempting to access Prescription Monitoring Program (PMP) patient information when prescribing Schedule II and IV controlled substances (with stated exceptions in the research text, e.g., certain oncology/palliative care or limited emergency department supplies). Compliance teams supporting prescribers and healthcare organizations should monitor because it could expand when PMP lookups and related documentation are required for controlled-substance prescribing workflows.
Illinois SB3507 (104th General Assembly) proposes amending Illinois Controlled Substances Act PMP-related requirements to expand/document attempts to access Prescription Monitoring Program data when prescribing Schedule II and IV controlled substances (with stated exceptions such as oncology/palliative care and certain emergency department scenarios). The latest recorded action in the research set indicates the bill was postponed in the Senate Licensed Activities committee on 2026-03-04. Compliance teams supporting prescribers/health systems should track this proposal because, if enacted, it could expand PMP query/documentation workflows and related audit expectations.
Illinois SB3507 (104th General Assembly) is pending legislation that would amend 720 ILCS 570/314.5 related to Prescription Monitoring Program (PMP) access/documentation when prescribing controlled substances. The research text indicates the bill would require prescribers (or designees) to document an attempt to access PMP patient information when issuing prescriptions for Schedule II and IV controlled substances, with exceptions (e.g., oncology/palliative; limited ED acute traumatic condition supplies). The research notes a recent committee action on 2026-03-04 (postponed in Licensed Activities). Compliance impact: could expand prescriber workflow/documentation obligations and system configuration for PMP lookups across additional schedules.
HB4796 (104th General Assembly) is a proposed amendment affecting 720 ILCS 570/201 that would require the Illinois Department of Human Services to reschedule a substance within 30 days after publication of a Federal Register final order if the DEA reschedules a Schedule I substance for mental health treatment purposes. If enacted, this could accelerate state controlled-substance scheduling alignment in Illinois following federal rescheduling actions, with downstream impacts for healthcare providers, dispensing controls, and compliance policies around newly rescheduled therapies.
An amendment (HB4953ham001) was filed that would tighten delivery controls for prescription drugs that are controlled substances by specifying that such products furnished by a licensed manufacturer/wholesale distributor may be delivered only to a registered place of business or professional practice as required by Section 302 of the Illinois Controlled Substances Act (720 ILCS 570/302). Compliance teams for manufacturers, wholesale distributors, and dispensers should monitor for enactment and be prepared to validate delivery-location registration status and update distribution SOPs and shipping controls accordingly.
Illinois HB5046 (104th General Assembly) was introduced on 2026-02-10 and proposes amendments impacting 720 ILCS 570/311.6 (electronic prescribing for Schedule II–V controlled substances). As described in the bill text, it would (1) require a dispenser/pharmacy that cannot fill an initial electronically received prescription due to out-of-stock conditions to immediately contact the patient and ask whether the prescription should be electronically transferred to a pharmacy of the patient’s choosing (consistent with 21 CFR 1306), and (2) expand/clarify exceptions to mandatory electronic prescribing where drugs may need to be filled outside typical retail hours or are difficult to obtain due to drug shortages/inventory limitations. The bill also contains conforming changes to the Pharmacy Practice Act (225 ILCS 85/19). Compliance teams at pharmacies, health systems, and prescriber organizations should monitor this bill because it would change operational workflows for patient communication and prescription transfer, and would adjust when non-electronic prescribing is permitted for controlled substances.
Illinois HB5046 (104th General Assembly) was introduced to amend 720 ILCS 570/311.6 (electronic prescribing of Schedule II–V controlled substances). As described in the research text, the proposal would require a dispenser/pharmacy that cannot fill an initially received electronic controlled-substance prescription due to being out of stock to immediately contact the patient and offer to electronically transfer the prescription to a pharmacy of the patient’s choosing (consistent with 21 CFR 1306). It would also add/clarify exceptions where a prescriber is not required to e-prescribe when timely access is impractical, including when filling may need to occur outside typical retail pharmacy hours or when drug shortages/inventory limitations apply. Compliance impact: pharmacy workflow changes, patient notification/transfer procedures, and prescriber documentation/decisioning around EPCS exceptions.
HB5046 was introduced to amend the Illinois Controlled Substances Act provisions on electronic prescribing (720 ILCS 570/311.6). As introduced, it would add requirements for dispensers when an initial controlled-substance prescription received electronically cannot be filled due to lack of stock (including immediate patient contact and an option to transfer electronically to another pharmacy), and it would clarify/expand circumstances where prescribers are not required to issue controlled-substance prescriptions electronically (e.g., drug shortages/inventory limitations and timing constraints). Compliance teams should track bill progress and assess impacts to EPCS workflows, patient notification procedures, and pharmacy transfer processes.
Illinois SB3521 (104th General Assembly) was introduced to amend 720 ILCS 570/318 to clarify that “one-to-one secure link” for Prescription Monitoring Program (PMP) communications includes communications exchange platforms aligned with widely adopted standards, including the Prescription Monitoring Information Exchange (PMIX) standard, to facilitate secure interstate transfer of PMP data. Compliance impact: may standardize acceptable technical mechanisms for interstate PMP interoperability and influence vendor certification/integration approaches for secure data exchange.
SB3521 (104th General Assembly) was introduced on 2026-02-05 and proposes amendments to 720 ILCS 570/318 (Confidentiality of information) relating to the prescriber and dispenser inquiry system (PMP). The proposal would clarify that a “one-to-one secure link” includes communications exchange platforms aligned with widely adopted standards (including PMIX) to facilitate secure (including cross-state) PMP data transfer. The introduced text also includes provisions to automatically create a log-in to the inquiry system when a prescriber/dispenser obtains or renews a controlled substance license, and to require IDFPR to provide the PMP with electronic access to license information to facilitate profile creation. If enacted, it would affect prescriber/dispenser PMP access workflows, identity provisioning, and technical interoperability planning for organizations operating in Illinois.
Illinois SB3764 (104th General Assembly) was introduced to amend 720 ILCS 570/312 (requirements for dispensing controlled substances). The proposal would retain the existing approach of allowing up to three sequential 30-day prescriptions totaling a 90-day supply, and additionally would allow (for non-opioid, non-narcotic Schedule II controlled substances) dispensing a 90-day supply at one time (not exceeding 90 days). Compliance teams supporting pharmacies and prescribers should monitor this bill because it would change permissible dispensing quantities/dispensing workflows for certain Schedule II medications in Illinois.
Illinois HB4602 (104th General Assembly) was introduced to amend 720 ILCS 570/316.1 regarding Prescription Monitoring Program (PMP) integration and interstate data sharing. As described in the research text, the bill would require interstate PMP data-sharing agreements to be “mutual” (i.e., Illinois would only share PMP data if the reciprocal state provides Illinois-licensed healthcare entities and application vendors an opportunity to access that state’s PMP data). Compliance impact: could affect cross-border PMP query workflows, interoperability arrangements, and contracts/technical integrations used by prescribers, dispensers, and PMP/EHR integration vendors.
Illinois SB3323 (104th General Assembly) was introduced to amend 720 ILCS 570/316 and add new 720 ILCS 570/316.2. As described in the research text, the bill would provide that the Illinois Prescription Monitoring Program does not apply to specified drugs (testosterone, mifepristone, misoprostol, GnRH analogues, estrogen). It would also require the Illinois Department of Human Services to purge existing PMP records concerning testosterone by January 1, 2027 and adopt/update implementing rules by January 1, 2027. Compliance impact: could change PMP reporting/recordkeeping scope for dispensers and PMP system operators, and require data retention/deletion processes tied to testosterone records.
SB3191 (104th General Assembly) was introduced on 2026-02-02 and proposes amendments to the Illinois Controlled Substances Act (including 720 ILCS 570/401 and 720 ILCS 570/401.1) to increase/modify fentanyl-related criminal penalties. As summarized in the introduced bill text, it would make unlawfully selling or dispensing any scheduled drug containing a detectable amount of fentanyl a Class X felony with specified sentencing/fine provisions, and would add a felony provision for knowingly using an electronic communication device in furtherance of controlled substance trafficking involving any amount of fentanyl (in addition to other penalties). Compliance and risk teams in healthcare/pharmacy and regulated distribution should monitor because changes could affect enforcement risk, diversion prevention programs, and reporting/escalation practices around suspected fentanyl diversion or illicit distribution.
SB3221 is pending legislation that would amend the Illinois Controlled Substances Act by adding xylazine as a Class III controlled substance and making related structural changes to controlled substance lists/definitions, while carving out specified exemptions (e.g., certain veterinary/animal-drug and professional use contexts). The ILGA bill status reflects a latest action of referral to Senate Assignments (2/02/2026). The synopsis indicates a proposed effective date of January 1, 2027. Compliance teams should monitor whether xylazine becomes scheduled in Illinois, evaluate supply chain and dispensing controls, and review applicability of any exemptions for veterinary and other permitted uses.
SB3191 is proposed legislation to amend the Illinois Controlled Substances Act provisions (including 720 ILCS 570/401 and 720 ILCS 570/401.1) by increasing penalties for certain fentanyl-related conduct. As described in the bill materials, it would make unlawfully selling/dispensing any scheduled drug containing a detectable amount of fentanyl a Class X felony (with specified imprisonment range and fines), and it would add a separate Class 1 felony for knowingly using an electronic communication device in furtherance of controlled substance trafficking involving fentanyl. The ILGA bill status shows the bill was referred to Senate Assignments on 2/02/2026. Compliance teams should monitor for enactment and prepare for potential updates to controlled-substance compliance programs, training, and risk assessments tied to fentanyl-containing products and communications evidence.
SB3221 (104th General Assembly) proposes adding xylazine as a Class III (Schedule III) controlled substance under the Illinois Controlled Substances Act while providing that xylazine is not considered a controlled substance in specified circumstances (exemptions for certain legitimate uses). The bill PDF text indicates an effective date of 2027-01-01. Organizations that handle xylazine (including veterinary and related regulated activities) should monitor because scheduling would impose controlled-substance controls unless an exemption applies.